Anbogen Therapeutics is developing precision oncology drugs that utilize targeted therapy to address the unmet medical needs of cancer patients. Their approach integrates scientific research with clinical development to create therapies that aim to improve patient outcomes in various cancer types.
Funding
$19.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients do not respond to traditional treatments, and there is a significant unmet need for therapies that can target specific cancer drivers. Traditional cancer treatments often have systemic side effects, highlighting the need for more precise and targeted approaches.
Solution
Anbogen Therapeutics develops precision oncology drugs designed to target specific molecular vulnerabilities within cancer cells. Their approach integrates research findings with clinical development to create targeted therapies aimed at improving patient outcomes across various cancer types. By focusing on targeted therapy, Anbogen aims to deliver personalized treatments that are more effective and less toxic than conventional chemotherapy or radiation. Their pipeline includes drugs designed to address unmet medical needs in cancers with specific genetic mutations or signaling pathway dysregulation.
Target Audience
The primary target audience includes cancer patients who are not responding to traditional treatments, as well as oncologists and researchers seeking more effective and targeted therapeutic options.
Features
- Focus on targeted therapy in precision oncology
- Integrates research findings with clinical development
- Pipeline of drugs designed to address unmet medical needs in various cancer types